2025 Clinical Neuromuscular Pathology Reading List

Reading List

Please click below to access the 2025 Clinical Neuromuscular Pathology reading list.

C-cert Activity Description

The Continuous Certification (C-cert) activities provide subspecialty learning and knowledge assessment to ensure that diplomates are staying up to date on the latest science, treatments, and therapeutics relating to their subspecialty. The annual activities include: 1) reading the subspecialty  journal articles, and 2) taking and passing the 25-question online post-reading quiz to assess knowledge gained from the journal article content. 

Learning Objectives

• Recognize clinicopathological features of infective myositis, immune-mediated necrotizing myopathies, and anti-ku myositis, including their mechanisms and therapy
• Identify the pathologic features of glycogen storage disease type IV and inherited and acquired sporadic late-onset nemaline myopathies
• Describe histopathological features indicative of the onset and progression of hereditary transthyretin amyloidosis
• Discuss the histopathological features and management of primary perineuritis and of acquired immune-mediated peripheral nerve disorders

Core Competencies

• Medical Knowledge
• Patient Care
• Practice-Based Learning and Improvement

Continuing Medical Education (CME) Instructions

To claim CME credits, answer question 26 on the quiz to reflect the total time spent completing the required reading and online quiz. This question is not included in the scoring of the quiz. A passing score of 80% of higher is needed to meet C-cert requirements and receive CME credit. CME credit confirmation will be emailed within 24 hours of passing the quiz.

ACCME Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Academy of Neurology Institute (AANI) and United Council for Neurologic Subspecialties. The AANI is accredited by the ACCME to provide continuing medical education for physicians.

AMA Credit Designation Statement

The American Academy of Neurology Institute designates this enduring material for a maximum of 15 AMA PRA Category 1^TM credit(s). Physicians should claim only their credit commensurate with the extent of the participation in the activity.

ABPN Self-Assessment Designation Statement

The American Board of Psychiatry and Neurology (ABPN) has reviewed the UCNS Continuous Certification (C-cert) self-assessment activity and has approved this activity as part of a comprehensive self-assessment (SA) CME activity, which is mandated by the American Board of Medical Specialties (ABMS) as a necessary component of continuing certification.

Disclosures

The UCNS complies with all standards and policies of the ACCME, including identification and resolution of all conflicts of interest prior to the educational activity being delivered to learners. Accordingly, UCNS  planners, authors, and staff comply with the UCNS’s Conflicts of Interest Policy. 

2025 C-cert Activity Planner (Certification Council) Disclosures
All relevant financial relationships have been mitigated.

Clinical Neuromuscular Pathology Certification Examination Committee Contributors

Mazen Mohammad Dimachkie, MD, Chair, University of Kansas Medical Center
Disclosures: Receives compensation for consulting with Abata/Third Rock, Abcuro, Amicus, ArgenX, Astellas, Cabaletta Bio, Catalyst, CNSA, Covance/Labcorp, CSL-Behring, Dianthus, Horizon, EMD Serono/Merck, Ig Society, Inc, Ipsen, Janssen, Medlink, Nuvig, Octapharma, Priovant, Sanofi Genzyme, Shire Takeda, TACT/Treat NMD, UCB Biopharma, Valenza Bio and Wolters Kluwer Health/UpToDate; receives compensation for serving on advisory board for Abata/Third Rock, Abcuro, Amicus, ArgenX, Astellas, Cabaletta Bio, Catalyst, CNSA, Covance/Labcorp, CSL-Behring, Dianthus, Horizon, EMD Serono/Merck, Ig Society, Inc, Ipsen, Janssen, Medlink, Nuvig, Octapharma, Priovant, Sanofi Genzyme, Shire Takeda, TACT/Treat NMD, UCB Biopharma, Valenza Bio and Wolters Kluwer Health/UpToDate; receives compensation for serving on speakers bureau for Abata/Third Rock, Abcuro, Amicus, ArgenX, Astellas, Cabaletta Bio, Catalyst, CNSA, Covance/Labcorp, CSL-Behring, Dianthus, Horizon, EMD Serono/Merck, Ig Society, Inc, Ipsen, Janssen, Medlink, Nuvig, Octapharma, Priovant, Sanofi Genzyme, Shire Takeda, TACT/Treat NMD, UCB Biopharma, Valenza Bio and Wolters Kluwer Health/UpToDate; received research grants or contracts or educational grants from Alexion/ AstraZeneca, Alnylam Pharmaceuticals, Amicus, Argenx, Bristol-Myers Squibb, Catalyst, CSL-Behring, FDA/OOPD, GlaxoSmithKline, Genentech, Grifols, Mitsubishi Tanabe Pharma, MDA, NIH, Novartis, Octapharma, Orphazyme, Ra Pharma/UCB, Sanofi Genzyme, Sarepta Therapeutics, Shire Takeda, Spark Therapeutics, The Myositis Association, and UCB Biopharma / RaPharma; holds patents, royalties, or other intellectual property interest from/with a discovery or technology relating to health care with UpToDate; receives compensation for other activities with Abata/Third Rock, Abcuro, Amicus, ArgenX, Astellas, Cabaletta Bio, Catalyst, CNSA, Covance/Labcorp, CSL-Behring, Dianthus, Horizon, EMD Serono/Merck, Ig Society, Inc, Ipsen, Janssen, Medlink, Nuvig, Octapharma, Priovant, Sanofi Genzyme, Shire Takeda, TACT/Treat NMD, UCB Biopharma, Valenza Bio and Wolters Kluwer Health/UpToDate; in the past two years has served on NM Review Course.

Ahmed Mohamed Attia El-Dokla, Vice Chair, MD, NY Neuromuscular Healthcare, PC
Disclosures: Nothing to disclose.

Michelle Lynn Mauermann, MD, Mayo Clinic – Rochester
Disclosures: Received research support from Alnylam and IONIS for research funding for clinical trial.

Rocio Carolina Garcia Santibanez, MD, Emory Brain Health Center
Disclosures: Received Honoraria for being editor for current treatment options in neurology.

Robert Bucelli, MD, Washington University School of Medicine in St. Louis
Disclosures: Paid consultant for Biogen. Serve on advisory boards for Biogen and Regeneron. Hold equity in Neuroquestions.com along with wife. Served as expert witness on two medicolegal cases, serving as expert witness for the defendant in both cases. Serve as site PI for a number of Biogen-sponsored ASO trials.

Raghav Govindarajan, MD, St. Elizabeth Medical Group, Illinois
Disclosures: Received compensation as a consultant and for serving on speakers bureau for Alexion, Argenx, UCB, Amgen.

Margherita Milone, MD, PhD, Mayo Clinic – Rochester
Disclosures: Received compensation for participation on one advisory board meeting on treatment of myasthenia gravis with Argenx in November 2022; receives compensation as Associate Editor of Neurology Genetics; received research support from Minnesota Regenerative Medicine, Muscular Dystrophy Association, Mayo Clinic.

Suur Biliciler, MD, University of Texas Health Science Center
Disclosures: Nothing to disclose.

Anthony A. Amato, MD, Brigham and Women's Hospital
Disclosures: Disclosures: Receives compensation for serving as a consultant for Medical Advisory Boards /Consultant for Abcuro, Argenx, Ra Pharmaceuticals, Horizon Therapeutics, OnoPharma, Alexion, EMD Serono, Takeda, Johnson & Johnson (COVID-19 vaccination program); Receives compensation for serving on advisory board for DSMB for Cabaletta (CAR-T myositis trial), Sirolimus in IBM trial, and Medpace (A Phase 1/2, First in Human, Multiple-dose, 2-part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NS-050/NCNP-03 in Boys with Duchenne Muscular Dystrophy); receives compensation for role as Associate Editor for Neurology; has received compensation as expert witness on several malpractice cases; received research support from NIH.

Mohamed Kazamel, MD, University of Alabama at Birmingham
Disclosures: Nothing to disclose.

Staff Contact

Bryan Hagerla, Continuous Certification Manager
Disclosures: Nothing to disclose.
[email protected]
(612) 928-6326